Comparison of Insulin Lispro Mix 25 with Insulin Lispro Mix 50 As Insulin Starter in Chinese Patients with Type 2 Diabetes Mellitus (CLASSIFY Study): Subgroup Analysis of a Phase 4 Open-Label Randomized Trial.

Qing Su,Chao Liu,Hongting Zheng,Jun Zhu,Peng Fei Li,Lei Qian,Wen Ying Yang

DOI: https://doi.org/10.1111/1753-0407.12442

IF: 4.53

2016-01-01

Journal of Diabetes

Abstract:Background: Premixed insulins are recommended starter insulins in Chinese patients after oral antihyperglycemic medication (OAM) failure. In the present study, we compared the efficacy and safety of insulin lispro mix 25 (LM25) twice daily (b.i.d.) and insulin lispro mix 50 (LM50) b.i.d. as a starter insulin regimen in Chinese patients with type 2 diabetes mellitus (T2DM) who had inadequate glycemic control with OAMs.Methods: The primary efficacy outcome in the present open-label parallel randomized clinical trial was change in HbA1c from baseline to 26 weeks. Patients were randomized in a ratio of 1: 1 to LM25 (n = 80) or LM50 (n = 76). A mixed-effects model with repeated measures was used to analyze continuous variables. The Cochran-Mantel-Haenszel test with stratification factor was used to analyze categorical variables.Results: At the end of the study, LM50 was more efficacious than LM25 in reducing mean HbA1c levels (least-squares [LS] mean difference 0.48; 95 % confidence interval [CI] 0.22, 0.74; P < 0.001). More subjects in the LM50 than LM25 group achieved HbA1c targets of <7.0 % (72.4 % vs 45.0 %; P = 0.001) or = 6.5 % (52.6 % vs 20.0 %; P < 0.001). Furthermore, LM50 was more effective than LM25 at reducing HbA1c in patients with baseline HbA1c, blood glucose excursion, and postprandial glucose greater than or equal to median levels (P <= 0.001). The rate and incidence of hypoglycemic episodes and increase in weight at the end of the study were similar between treatment groups.Conclusions: In Chinese patients with T2DM, LM50 was more efficacious than LM25 as a starter insulin.